Drug-Related Side Effects and Adverse Reactions - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	Drug-Related Side Effects and Adverse Reactions	go back to main search page
Accession:	DOID:9006810	browse the term
Definition:	Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Synonyms:	exact_synonym:	Adverse Drug Reaction; Adverse Drug Reactions; Drug Side Effect; Drug Side Effects; Drug Toxicities; adverse drug event; adverse drug events; drug toxicity; side effects of drugs
	narrow_synonym:	antidepressant-induced dizziness
	related_synonym:	Brain pseudoatrophy, reversible, valproate-induced, susceptibility to
	primary_id:	MESH:D064420
	xref:	EFO:0006321; EFO:0020003

show annotations for term's descendants Sort by:
Rat (667) Mouse (683) Human (1310) Chinchilla (516) Bonobo (564) Dog (633) Squirrel (521) Pig (612) Green Monkey (556) Naked Mole-rat (517) All
Genes (663) QTL (1) Strains (3)

Drug-Related Side Effects and Adverse Reactions

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

CTD Direct Evidence: marker/mechanism

PMID:18381794 PMID:20563569 PMID:21064136 PMID:24502637 PMID:25007187 More...

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 12

CTD Direct Evidence: marker/mechanism

NCBI chr19:20,549,298...20,621,991
Ensembl chr19:20,549,405...20,620,734

G

ATP binding cassette subfamily C member 2

CTD Direct Evidence: marker/mechanism

PMID:20216337 PMID:23222202 PMID:25007187 PMID:32387182

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 4

CTD Direct Evidence: marker/mechanism

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

CTD Direct Evidence: marker/mechanism

PMID:21064136 PMID:32387182

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409

G

acetylcholinesterase

CTD Direct Evidence: therapeutic

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651

G

adenosine A1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,853...13,333,386

G

afamin

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,815,194...17,848,042
Ensembl chr14:17,531,024...17,563,870

G

alpha-2-HS-glycoprotein

CTD Direct Evidence: marker/mechanism

NCBI chr11:91,625,975...91,632,583
Ensembl chr11:78,117,918...78,145,999

G

albumin

CTD Direct Evidence: marker/mechanism

PMID:24361871 PMID:28885000

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: marker/mechanism

NCBI chr 5:81,583,621...81,593,938
Ensembl chr 5:76,568,094...76,578,331

G

apolipoprotein B

CTD Direct Evidence: marker/mechanism

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:30,844,368...30,892,497

G

AT-rich interaction domain 5B

CTD Direct Evidence: marker/mechanism

NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,307,731...20,487,433

G

argininosuccinate synthase 1

protein:increased expression:plasma (rat)

RGD

NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:14,747,368...14,796,903

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

CTD Direct Evidence: marker/mechanism

NCBI chr 9:80,614,311...80,634,360
Ensembl chr 9:73,164,846...73,184,889

G

beta-2 microglobulin

CTD Direct Evidence: marker/mechanism

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:109,095,729...109,101,766

G

butyrylcholinesterase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:158,307,584...158,401,148

G

complement C3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,087,437...2,114,429

G

calcium voltage-gated channel subunit alpha1 H

CTD Direct Evidence: marker/mechanism

NCBI chr10:14,894,630...14,952,317
Ensembl chr10:14,390,113...14,448,376

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

associated with colon cancer

RGD

NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:150,673,507...150,676,600

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231

G

cytidine deaminase

DNA:SNP:cds:rs1048977|rs12726436|rs2072671 (human)

RGD

NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231

G

carboxylesterase 2H

CTD Direct Evidence: marker/mechanism

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:32,974,242...32,988,830

G

clusterin

CTD Direct Evidence: marker/mechanism

PMID:24361871 PMID:28885000

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315

G

copper metabolism domain containing 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:101,081,667...101,185,738
Ensembl chr14:96,880,463...96,984,501

G

ceruloplasmin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:102,439,624...102,498,075

G

colony stimulating factor 2

CTD Direct Evidence: therapeutic

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:7692001 PMID:27737899 PMID:31557154

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603

G

cystatin C

CTD Direct Evidence: marker/mechanism

NCBI chr 3:156,790,061...156,794,116
Ensembl chr 3:136,336,920...136,340,822

G

cytochrome P450, family 1, subfamily a, polypeptide 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily c, polypeptide 79

CTD Direct Evidence: marker/mechanism

G

cytochrome P450, family 2, subfamily d, polypeptide 4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023

G

dihydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:25,320,895...25,346,004
Ensembl chr 2:23,586,031...23,613,713

G

disco-interacting protein 2 homolog B

CTD Direct Evidence: marker/mechanism

NCBI chr 7:133,053,393...133,231,430
Ensembl chr 7:131,174,567...131,349,092

G

dihydropyrimidine dehydrogenase

DNA:SNP:cds:rs12119882 (human)

RGD

NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:206,609,122...207,474,982

G

enolase superfamily member 1

DNA:SNP:cds:rs699517 (human)

RGD

NCBI chr 9:113,275,267...113,314,842

G

Eph receptor A7

CTD Direct Evidence: marker/mechanism

NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:42,975,405...43,127,112

G

epoxide hydrolase 2

CTD Direct Evidence: therapeutic

NCBI chr15:44,465,447...44,503,157
Ensembl chr15:40,289,902...40,327,615

G

ERCC excision repair 1, endonuclease non-catalytic subunit

treatment

associated with Breast Neoplasms;DNA:SNP: :p.Q504K (human)
associated with Leukemia, Myeloid, Acute

RGD

PMID:25495407 PMID:17197435

RGD:11252168, RGD:11252178

NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 2, TFIIH core complex helicase subunit

treatment

DNA:SNP: :p.K751Q (rs13181) (human)
associated with Leukemia, Myeloid, Acute;DNA:SNPs, haplotypes: :p.D312N, p.K751Q (human)

RGD

PMID:15339847 PMID:17197435

RGD:11252202, RGD:11252178

NCBI chr 1:88,161,342...88,175,102
Ensembl chr 1:79,033,326...79,047,102

G

fibrinogen alpha chain

CTD Direct Evidence: marker/mechanism

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:168,374,120...168,381,528

G

fibronectin type III domain containing 3B

CTD Direct Evidence: marker/mechanism

NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:110,312,694...110,547,830

G

GATA binding protein 4

CTD Direct Evidence: marker/mechanism

NCBI chr15:41,635,572...41,707,252
Ensembl chr15:37,459,601...37,505,636

G

GATA binding protein 6

CTD Direct Evidence: marker/mechanism

NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,188,121...2,219,532

G

GC, vitamin D binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr14:18,916,255...18,951,670
Ensembl chr14:18,632,135...18,667,567

G

glutathione S-transferase alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121

G

hepatitis A virus cellular receptor 1

CTD Direct Evidence: marker/mechanism

PMID:15805072 PMID:24361871 PMID:28885000

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698

G

high mobility group box 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:24,543,093...24,644,785

G

haptoglobin

CTD Direct Evidence: marker/mechanism

NCBI chr19:54,449,151...54,453,701
Ensembl chr19:37,539,627...37,544,523

G

hemopexin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:159,932,755...159,940,328

G

heat shock protein family B (small) member 6

CTD Direct Evidence: therapeutic

NCBI chr 1:94,934,372...94,936,516
Ensembl chr 1:85,806,146...85,809,071

G

5-hydroxytryptamine receptor 2B

CTD Direct Evidence: marker/mechanism

NCBI chr 9:94,184,442...94,206,851
Ensembl chr 9:86,742,102...86,755,108

G

interferon gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

CTD Direct Evidence: therapeutic

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:82,047,415...82,052,482

G

gamma-2a immunoglobulin heavy chain

CTD Direct Evidence: marker/mechanism

G

interleukin 10

CTD Direct Evidence: marker/mechanism

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 receptor antagonist

CTD Direct Evidence: marker/mechanism

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 3

CTD Direct Evidence: therapeutic

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,405,716...38,408,066

G

interleukin 6

CTD Direct Evidence: marker/mechanism

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

KIT ligand

CTD Direct Evidence: therapeutic

NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:34,896,053...34,977,214

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095

G

lymphotoxin beta receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:159,795,115...159,801,571
Ensembl chr 4:158,108,886...158,121,539

G

mitogen activated protein kinase 14

susceptibility

associated with lung non-small cell carcinoma;DNA:SNP:3' utr, intron: (rs3804451) (human)

RGD

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589

G

molybdenum cofactor sulfurase

CTD Direct Evidence: marker/mechanism

NCBI chr18:16,206,402...16,251,928
Ensembl chr18:15,931,654...15,977,187

G

mitochondrially encoded ATP synthase membrane subunit 8

ClinVar Annotator: match by term: Brain pseudoatrophy, reversible, valproate-induced, susceptibility to

PMID:9243242 PMID:17101920

NCBI chr MT:7,758...7,961
Ensembl chr MT:7,758...7,961

G

methylenetetrahydrofolate reductase

CTD Direct Evidence: marker/mechanism

PMID:15753437 PMID:16166815 PMID:17387702 PMID:17502830 PMID:18551038 More...

NCBI chr 5:163,748,346...163,768,141
Ensembl chr 5:158,465,296...158,483,797

G

5-methyltetrahydrofolate-homocysteine methyltransferase

CTD Direct Evidence: marker/mechanism

PMID:15753437 PMID:19159907

NCBI chr17:62,911,705...62,996,544
Ensembl chr17:58,220,071...58,304,822

G

5-methyltetrahydrofolate-homocysteine methyltransferase reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:36,695,376...36,727,341
Ensembl chr 1:34,867,089...34,899,425

G

murinoglobulin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:156,748,351...156,802,132
Ensembl chr 4:155,076,312...155,130,051

G

N-acetyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:26,984,882...27,005,194
Ensembl chr16:22,208,194...22,238,520

G

N-acetyltransferase 2

susceptibility

DNA:polymorphism: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:17377643 PMID:17502830 PMID:12786839

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: therapeutic

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737

G

nuclear receptor subfamily 3, group C, member 1

CTD Direct Evidence: marker/mechanism

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375

G

5'-nucleotidase, cytosolic II

CTD Direct Evidence: marker/mechanism

NCBI chr 1:255,712,797...255,838,285
Ensembl chr 1:245,772,277...245,897,913

G

neurotrimin

susceptibility

associated with hypertension;DNA:SNPs: :rs2511774, rs139945292, rs80175218

RGD

NCBI chr 8:35,634,929...36,625,081
Ensembl chr 8:27,377,773...28,366,595

G

orosomucoid 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:76,772,941...76,776,154

G

pellino E3 ubiquitin protein ligase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:99,455,970...99,510,474
Ensembl chr14:95,254,589...95,308,285
Ensembl chr 1:95,254,589...95,308,285

G

plasminogen

CTD Direct Evidence: marker/mechanism

NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:48,325,185...48,367,786

G

polo-like kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:41,969,176...41,974,947

G

peroxisome proliferator activated receptor alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

renin

CTD Direct Evidence: marker/mechanism

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:44,796,091...44,807,489

G

urinary protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:35,336,764...35,340,345
Ensembl chr 8:35,336,764...35,489,103

G

serpin family A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:122,866,312...122,888,339

G

serine hydroxymethyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:45,968,959...45,990,341
Ensembl chr10:45,468,700...45,497,820

G

solute carrier family 19 member 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:11,583,928...11,601,959
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 22 member 7

DNA:SNP:cds:rs2270860|rs4149178 (human)

RGD

NCBI chr 9:22,044,672...22,052,051
Ensembl chr 9:14,547,849...14,553,921

G

solute carrier family 34 member 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier organic anion transporter family, member 2a1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:112,467,739...112,551,923
Ensembl chr 8:103,588,916...103,672,546

G

superoxide dismutase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249

G

secreted phosphoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162

G

transcobalamin 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:83,036,935...83,052,187
Ensembl chr14:78,813,343...78,828,489

G

transferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:103,767,995...103,816,511

G

thrombomodulin

CTD Direct Evidence: therapeutic

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:135,862,835...135,867,193

G

toll-like receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:43,737,761...43,750,389
Ensembl chr14:43,384,932...43,397,125

G

toll-like receptor 2

CTD Direct Evidence: marker/mechanism

PMID:18466103 PMID:31557154

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

DNA topoisomerase I

CTD Direct Evidence: marker/mechanism

NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:149,293,403...149,376,623

G

tumor protein p53

CTD Direct Evidence: marker/mechanism

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

transthyretin

CTD Direct Evidence: marker/mechanism

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:11,943,789...11,951,008

G

thioredoxin 1

CTD Direct Evidence: therapeutic

NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629

G

thymidylate synthetase

CTD Direct Evidence: marker/mechanism
DNA:SNP:cds:rs2853741 (human)

CTD
RGD

PMID:19648163 PMID:21064136 PMID:25007187 PMID:26077125 PMID:28347776

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536

G

UDP glucuronosyltransferase family 1 member A1

CTD Direct Evidence: therapeutic

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

uridine monophosphate synthetase

DNA:SNP:cds:rs2279199|rs4678145 (human)

RGD

NCBI chr11:80,311,269...80,321,678
Ensembl chr11:66,806,045...66,821,903

G

vascular endothelial growth factor A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641

G

vitamin K epoxide reductase complex, subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:191,932,969...191,935,490
Ensembl chr 1:182,500,844...182,505,008

Anthracycline-induced Cardiotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

susceptibility

DNA:missense mutation:cds:p.G671V (human)

RGD

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

activin A receptor type 2B

treatment

human construct in mouse model

RGD

NCBI chr 8:128,016,589...128,056,193
Ensembl chr 8:119,138,812...119,170,458

G

calpain 2

treatment

RGD

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:94,150,240...94,200,969

G

ERCC excision repair 2, TFIIH core complex helicase subunit

associated with Leukemia, Myeloid, Acute;DNA:SNP:exon:p.K751Q (rs13181) (human)

RGD

NCBI chr 1:88,161,342...88,175,102
Ensembl chr 1:79,033,326...79,047,102

aspirin-induced respiratory disease

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcium voltage-gated channel auxiliary subunit gamma 6

susceptibility

DNA:SNP,haplotype:rs192808(human)

RGD

NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341

G

C-C motif chemokine receptor 3

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:20022477

NCBI chr 8:132,463,533...132,511,601
Ensembl chr 8:123,616,236...123,634,990

G

cysteinyl leukotriene receptor 1

CTD Direct Evidence: marker/mechanism

PMID:16502481 PMID:17641958 PMID:20485159

NCBI chr X:75,734,281...75,762,873
Ensembl chr X:71,663,821...71,690,121

G

cysteinyl leukotriene receptor 2

DNA:SNPs: :-819T>G, 2078C>T, 2534A>G (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:15970796

NCBI chr15:54,599,043...54,638,314
Ensembl chr15:48,189,073...48,304,136

G

FA complementation group C

DNA:haplotype::rs4647416(human)

RGD

NCBI chr17:1,686,374...1,818,672
Ensembl chr17:1,681,324...1,829,376

G

interleukin 4

susceptibility

DNA:SNPs:promoter,5'UTR,intron:multiple

RGD

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

leukotriene C4 synthase

CTD Direct Evidence: marker/mechanism

PMID:9393345 PMID:9466979 PMID:10970818 PMID:20485159

NCBI chr10:35,060,002...35,066,466
Ensembl chr10:34,560,360...34,562,651

G

membrane spanning 4-domains A2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:217,864,855...217,873,934
Ensembl chr 1:208,440,361...208,448,310

G

periostin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:138,527,696...138,559,099

G

prostaglandin D2 receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:217,010,183...217,015,044
Ensembl chr 1:207,587,917...207,589,213

G

prostaglandin E receptor 2

ClinVar Annotator: match by term: Asthma, aspirin-induced, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:15496426 PMID:16502481

NCBI chr15:20,694,765...20,708,475
Ensembl chr15:18,217,285...18,228,714

G

prostaglandin I2 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:86,707,690...86,710,073
Ensembl chr 1:77,579,596...77,581,979

G

prostaglandin-endoperoxide synthase 2

protein:increased expression:mast cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:9487340

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

RT1 class II, locus Ba

susceptibility

RGD

NCBI chr20:4,577,057...4,581,650
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

susceptibility

RGD

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus Db1

susceptibility

RGD

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,548,666...4,558,258

G

RT1 class II, locus Hb, pseudogene 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,777,494...4,781,486
Ensembl chr20:4,774,650...4,780,618

G

transporter 2, ATP binding cassette subfamily B member

RGD

NCBI chr20:4,638,257...4,652,296
Ensembl chr20:4,636,357...4,650,407

G

T-box transcription factor 21

ClinVar Annotator: match by term: Asthma, aspirin-induced, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:15806396 PMID:16502481

NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,082,322...82,098,831

G

thromboxane A2 receptor

susceptibility

DNA:polymorphism: :795T>C (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:15898979

NCBI chr 7:9,034,077...9,041,489
Ensembl chr 7:8,383,378...8,388,176

asthma, nasal polyps, and aspirin intolerance

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 15-lipoxygenase

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance

PMID:17959182 PMID:21558275 PMID:25741868 PMID:30643255

NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,060,412...55,068,874

G

leukotriene C4 synthase

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance

NCBI chr10:35,060,002...35,066,466
Ensembl chr10:34,560,360...34,562,651

G

prostaglandin E receptor 2

susceptibility

CTD Direct Evidence: marker/mechanism

NCBI chr15:20,694,765...20,708,475
Ensembl chr15:18,217,285...18,228,714

G

T-box transcription factor 21

susceptibility

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance
CTD Direct Evidence: marker/mechanism

ClinVar
OMIM
CTD

NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,082,322...82,098,831

Cardiotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase beta

mRNA, protein:increased expression:heart (rat)

RGD

NCBI chr12:48,026,394...48,138,214
Ensembl chr12:42,366,548...42,457,655

G

angiotensinogen

CTD Direct Evidence: marker/mechanism

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977

G

butyrylcholinesterase

CTD Direct Evidence: therapeutic

NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:158,307,584...158,401,148

G

bone morphogenetic protein 2

CTD Direct Evidence: therapeutic

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397

G

catalase

CTD Direct Evidence: therapeutic

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226

G

carnitine palmitoyltransferase 1A

mRNA, protein:decreased expression:heart (rat)

RGD

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

colony stimulating factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:195,377,215...195,411,704

G

Fas cell surface death receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

CTD Direct Evidence: marker/mechanism

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215

G

FTO, alpha-ketoglutarate dependent dioxygenase

DNA:hypermethylation:promoter

RGD

NCBI chr19:31,456,749...31,865,011
Ensembl chr19:15,349,696...15,692,083

G

heparin-binding EGF-like growth factor

CTD Direct Evidence: therapeutic

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,105,760...28,116,441

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

potassium calcium-activated channel subfamily N member 2

CTD Direct Evidence: therapeutic

PMID:32909839 PMID:33887967

NCBI chr18:40,004,693...40,445,043
Ensembl chr18:37,817,957...38,258,347

G

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 2:214,215,165...214,231,412
Ensembl chr 2:211,530,602...211,546,821

G

microRNA 143

ameliorates

RGD

NCBI chr18:57,371,349...57,371,453
Ensembl chr18:55,101,006...55,101,110

G

microRNA 208a

CTD Direct Evidence: marker/mechanism

NCBI chr15:32,395,552...32,395,634

G

malonyl-CoA decarboxylase

protein:increased expression:heart (rat)

RGD

NCBI chr19:64,356,582...64,372,447
Ensembl chr19:47,447,970...47,463,793

G

nitric oxide synthase 3

treatment

associated with Precursor Cell Lymphoblastic Leukemia-Lymphoma;DNA:polymorphism: :894G>T(human)

RGD

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166

G

natriuretic peptide B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:158,416,866...158,418,168

G

neuregulin 1

CTD Direct Evidence: therapeutic

NCBI chr16:65,954,084...67,007,484
Ensembl chr16:59,250,854...60,296,884

G

protein kinase AMP-activated catalytic subunit alpha 2

protein:decreased expression:serum, heart (rat)

RGD

NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543

G

Rac family small GTPase 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251

G

retinoic acid receptor, gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:135,246,427...135,268,889
Ensembl chr 7:133,367,833...133,390,177

G

ring finger protein 10

CTD Direct Evidence: therapeutic

NCBI chr12:47,002,409...47,036,201
Ensembl chr12:41,341,717...41,375,504

G

sirtuin 6

CTD Direct Evidence: therapeutic

NCBI chr 7:8,733,056...8,738,543
Ensembl chr 7:8,082,364...8,098,914

G

toll-like receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:29959987 PMID:32068018

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

CTD Direct Evidence: marker/mechanism

PMID:30009776 PMID:34713381

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

Chemical and Drug Induced Liver Injury

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate-semialdehyde synthase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:52,572,146...52,628,811
Ensembl chr 4:51,606,462...51,663,136

G

ATP binding cassette subfamily B member 11

severity

DNA:SNP: :rs2287616(human)

RGD

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

severity
susceptibility

DNA:SNP::2677G>T/A(rs2032582)(human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20623750 PMID:26134275 PMID:26134275 PMID:27296832

RGD:11041130, RGD:14700895

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

CTD Direct Evidence: marker/mechanism

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:polymorphism:promoter:-24C>T(human)

CTD
RGD

PMID:18381794 PMID:18466103 PMID:17241877 PMID:25196354

RGD:14700814, RGD:14700812

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

abl-interactor 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:90,006,917...90,088,002
Ensembl chr17:85,098,550...85,179,792

G

angiotensin I converting enzyme

mRNA:increased expression:liver (rat)

RGD

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131

G

acyl-CoA oxidase 3, pristanoyl

CTD Direct Evidence: marker/mechanism

NCBI chr14:79,358,604...79,405,160
Ensembl chr14:75,094,676...75,176,205

G

acyl-CoA synthetase long-chain family member 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:52,487,870...52,554,110
Ensembl chr16:45,755,254...45,821,541

G

actin, beta

mRNA:increased expression:liver
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:25231249 PMID:22563491

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:11,663,109...11,672,877

G

actinin alpha 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:93,310,294...93,379,369
Ensembl chr 1:84,182,788...84,251,847

G

actin related protein 3

CTD Direct Evidence: marker/mechanism

NCBI chr13:39,353,413...39,396,509
Ensembl chr13:36,800,093...36,844,124

G

adenosine deaminase

protein:increased expression:liver

RGD

NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 8

CTD Direct Evidence: marker/mechanism

NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:194,770,060...194,788,801

G

adiponectin, C1Q and collagen domain containing

CTD Direct Evidence: therapeutic

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564

G

adiponectin receptor 2

severity

associated with obesity, LPS;mRNA:decreased expression:liver (rat)

RGD

NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:152,524,623...152,559,355

G

adenosine A2B receptor

CTD Direct Evidence: therapeutic

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:46,940,384...46,956,772

G

angiotensinogen

CTD Direct Evidence: marker/mechanism

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

CTD Direct Evidence: marker/mechanism|therapeutic
mRNA:decreased expression:liver (rat)

CTD
RGD

PMID:21890736 PMID:34848246 PMID:28959666

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:127,650,226...127,689,256

G

adenylate kinase 4

protein:increased expression:liver (rat)

RGD

NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:116,039,616...116,098,618

G

aldo-keto reductase family 1 member A1

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:32805337 PMID:29763686

NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:130,092,732...130,113,674

G

albumin

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18779383 PMID:22310181 PMID:27567545

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member L2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:20,254,233...20,305,776

G

aldehyde dehydrogenase 2 family member

severity
susceptibility

protein:increased expression:liver
DNA:deletion:exon 3 (mouse)

RGD

PMID:21138988 PMID:30121625 PMID:24492981

RGD:7241599, RGD:15036810, RGD:14975148

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 9 family, member A1

CTD Direct Evidence: marker/mechanism

NCBI chr13:82,038,679...82,055,478
Ensembl chr13:79,505,695...79,540,568

G

aldolase, fructose-bisphosphate B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:68,684,541...68,697,582
Ensembl chr 5:63,889,046...63,902,116

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: marker/mechanism

NCBI chr 5:81,583,621...81,593,938
Ensembl chr 5:76,568,094...76,578,331

G

annexin A2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:70,105,253...70,141,658

G

annexin A6

CTD Direct Evidence: marker/mechanism

NCBI chr10:39,602,106...39,657,183
Ensembl chr10:39,097,109...39,156,433

G

apolipoprotein A1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein E

CTD Direct Evidence: marker/mechanism

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein H

mRNA:increased expression:plasma:
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16099942 PMID:23288050

NCBI chr10:93,841,992...93,855,897
Ensembl chr10:93,310,977...93,356,329

G

arginase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:20,475,968...20,488,422

G

aryl hydrocarbon receptor nuclear translocator

CTD Direct Evidence: marker/mechanism

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:182,997,736...183,056,580

G

autophagy related 5

CTD Direct Evidence: marker/mechanism

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209

G

atonal bHLH transcription factor 8

CTD Direct Evidence: marker/mechanism

NCBI chr 4:105,818,203...105,850,379
Ensembl chr 4:104,259,992...104,292,168

G

ATPase H+ transporting V1 subunit D

CTD Direct Evidence: marker/mechanism

NCBI chr 6:97,656,725...97,672,295
Ensembl chr 6:97,656,576...97,672,303

G

arginine vasopressin

DNA:SNP:intron: (rs2282018)

RGD

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:117,793,457...117,795,425

G

BCL2-associated agonist of cell death

treatment

RGD

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

3-hydroxybutyrate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:82,806,125...82,848,133
Ensembl chr11:69,302,534...69,337,671

G

bradykinin receptor B2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:124,472,566...124,502,497

G

biliverdin reductase B

CTD Direct Evidence: marker/mechanism

NCBI chr 1:91,866,258...91,883,921
Ensembl chr 1:82,738,695...82,770,375

G

basic helix-loop-helix ARNT like 1

CTD Direct Evidence: therapeutic

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:167,331,633...167,430,231

G

3'(2'), 5'-bisphosphate nucleotidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:99,397,127...99,425,056
Ensembl chr13:96,868,580...96,893,503

G

bromodomain containing 4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:11,866,997...11,946,575
Ensembl chr 7:11,216,446...11,295,539

G

biotinidase

CTD Direct Evidence: marker/mechanism

NCBI chr16:6,863,068...6,894,345
Ensembl chr16:6,862,407...6,940,945

G

complement C3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,087,437...2,114,429

G

calcium binding protein 1

protein:increased expression:liver

RGD

NCBI chr12:47,045,914...47,109,614
Ensembl chr12:41,378,897...41,448,927

G

calcium dependent secretion activator 2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:52,746,054...53,275,252
Ensembl chr 4:51,781,053...52,309,829

G

calnexin

CTD Direct Evidence: marker/mechanism

NCBI chr10:35,124,941...35,157,954
Ensembl chr10:34,625,191...34,656,821

G

cyclase associated actin cytoskeleton regulatory protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:140,427,265...140,507,678
Ensembl chr 5:135,142,112...135,168,769

G

carbonic anhydrase 3

CTD Direct Evidence: marker/mechanism

PMID:25226513 PMID:25231249

NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:86,770,420...86,784,280

G

caspase 8

treatment

RGD

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

calpastatin

RGD

NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:3,973,112...4,082,659

G

catalase

CTD Direct Evidence: marker/mechanism
protein:decreased expression:liver

CTD
RGD

PMID:20623750 PMID:25231249 PMID:21138988

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 80

CTD Direct Evidence: marker/mechanism

NCBI chr11:69,191,188...69,224,844
Ensembl chr11:55,685,872...55,719,137

G

C-C motif chemokine ligand 2

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20623750 PMID:21813474 PMID:30663942

RGD:14995466, RGD:14995458

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 5

susceptibility

acetaminophen

RGD

NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:123,752,325...123,759,260

G

chaperonin containing TCP1 subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:173,765,698...173,790,757

G

chaperonin containing TCP1 subunit 5

CTD Direct Evidence: marker/mechanism

NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:82,590,630...82,602,930

G

cell division cycle 25B

CTD Direct Evidence: marker/mechanism

NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:118,407,128...118,417,272

G

CDP-diacylglycerol synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

chymotrypsin like elastase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:133,651,939...133,665,136
Ensembl chr 7:131,742,002...131,786,285

G

cilia and flagella associated protein 20

CTD Direct Evidence: marker/mechanism

NCBI chr19:9,614,265...9,628,612
Ensembl chr19:9,608,859...9,622,558

G

complement factor H

CTD Direct Evidence: marker/mechanism

NCBI chr13:54,063,079...54,164,523
Ensembl chr13:51,511,828...51,613,838

G

cholinergic receptor, muscarinic 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:64,696,549...65,158,622
Ensembl chr17:60,005,202...60,467,278

G

creatine kinase B

CTD Direct Evidence: marker/mechanism

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:130,729,423...130,732,315

G

clusterin

CTD Direct Evidence: marker/mechanism

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315

G

collagen type XIV alpha 1 chain

CTD Direct Evidence: marker/mechanism

NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:86,722,094...86,937,214

G

collagen type III alpha 1 chain

CTD Direct Evidence: marker/mechanism

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547

G

catechol-O-methyltransferase

protein:decreased expression:liver

RGD

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642

G

coenzyme Q9

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,172,943...10,185,960
Ensembl chr19:10,166,951...10,179,949

G

ceruloplasmin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:102,439,624...102,498,075

G

carboxypeptidase B2

mRNA,protein:increased expression,increased activity:liver,plasma

RGD

NCBI chr15:56,967,128...57,015,964
Ensembl chr15:50,557,717...50,606,556

G

carbamoyl-phosphate synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:76,063,863...76,186,739
Ensembl chr 9:68,614,153...68,737,033

G

carnitine palmitoyltransferase 1A

mRNA:decreased expression:liver (rat)

RGD

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 3

CTD Direct Evidence: therapeutic

PMID:20005281 PMID:33882750

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603

G

catenin beta 1

CTD Direct Evidence: therapeutic

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin E

CTD Direct Evidence: marker/mechanism

NCBI chr13:45,644,168...45,666,722
Ensembl chr13:43,092,128...43,114,502

G

C-X-C motif chemokine ligand 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

CTD Direct Evidence: therapeutic

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 14

CTD Direct Evidence: marker/mechanism

NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,317,933...8,324,839

G

C-X-C motif chemokine ligand 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511

G

cytochrome P450, family 1, subfamily a, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 27, subfamily b, polypeptide 1

mRNA, protein:decreased expression:kidney (mouse)

RGD

NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily b, polypeptide 3

CTD Direct Evidence: marker/mechanism

PMID:28762043 PMID:33814510

NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

CTD Direct Evidence: marker/mechanism

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

CTD Direct Evidence: marker/mechanism

PMID:12963435 PMID:28762043

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

DNA:hypermethylation:promoter

RGD

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

treatment

CTD Direct Evidence: marker/mechanism
DNA:hypermethylation:promoter
associated with Endotoxemia

CTD
RGD

PMID:12668988 PMID:16770646 PMID:21741958 PMID:28762043 PMID:27960551 More...

RGD:14700901, RGD:14700879, RGD:14700878, RGD:14700873, RGD:14700872

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

CTD Direct Evidence: marker/mechanism

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 4, subfamily a, polypeptide 3

CTD Direct Evidence: marker/mechanism

NCBI chr 5:134,334,396...134,352,268
Ensembl chr 5:129,097,926...129,115,463

G

cytochrome P450 family 8 subfamily B member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166

G

dihydrolipoamide branched chain transacylase E2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:207,166,660...207,195,528
Ensembl chr 2:204,481,737...204,510,609

G

damage-specific DNA binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:207,252,890...207,278,676

G

diacylglycerol O-acyltransferase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:153,454,080...153,484,428

G

dihydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:25,320,895...25,346,004
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 7

CTD Direct Evidence: marker/mechanism

NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:91,251,323...91,347,892

G

dihydrolipoamide S-acetyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

DnaJ heat shock protein family (Hsp40) member B9

CTD Direct Evidence: marker/mechanism

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C12

CTD Direct Evidence: marker/mechanism

NCBI chr20:25,245,475...25,266,238
Ensembl chr20:25,223,144...25,267,521

G

desmocollin 2

CTD Direct Evidence: marker/mechanism

NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,450,390...11,482,392

G

E2F transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361

G

ethylmalonyl-CoA decarboxylase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319

G

enoyl-CoA hydratase, short chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:194,895,036...194,903,884

G

ER degradation enhancing alpha-mannosidase like protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:143,350,989...143,385,693
Ensembl chr 4:141,797,701...141,829,717

G

eukaryotic translation initiation factor 2 alpha kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:15,824,431...15,858,266
Ensembl chr12:10,705,874...10,744,573

G

eukaryotic translation initiation factor 4E binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:29,922,260...29,942,922
Ensembl chr20:29,382,668...29,399,946

G

endonuclease G

protein:decreased expression:mitochondrion:

RGD

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:13,449,086...13,451,932

G

endoglin

protein:increased expression:liver (rat)

RGD

NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:15,934,518...15,973,230

G

enolase 1

CTD Direct Evidence: marker/mechanism

PMID:16099942 PMID:25231249

NCBI chr 5:166,002,867...166,014,252
Ensembl chr 5:160,719,951...160,731,336
Ensembl chr 3:160,719,951...160,731,336

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

protein:increased activity:serum:

RGD

NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:86,202,350...86,324,827

G

epoxide hydrolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:92,714,315...92,790,235

G

endoplasmic reticulum lectin 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:108,856,661...108,894,511
Ensembl chr14:104,655,673...104,693,480

G

endoplasmic reticulum to nucleus signaling 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029

G

coagulation factor XIII A1 chain

RGD

NCBI chr17:28,021,197...28,197,960
Ensembl chr17:27,815,702...27,992,700

G

F2R like thrombin or trypsin receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr16:17,151,516...17,153,509
Ensembl chr16:17,117,441...17,119,472

G

coagulation factor III, tissue factor

CTD Direct Evidence: marker/mechanism

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668

G

Fas associated via death domain

treatment

RGD

PMID:26062544 PMID:25447754

RGD:11341803, RGD:10053709

NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:199,739,994...199,745,653

G

fatty acid desaturase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid desaturase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

protein:increased expression:liver (rat)

RGD

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

fatty acid synthase

CTD Direct Evidence: marker/mechanism

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

Fc mu receptor

CTD Direct Evidence: marker/mechanism

NCBI chr13:44,889,628...44,903,926
Ensembl chr13:42,337,414...42,351,653

G

fibrinogen alpha chain

CTD Direct Evidence: marker/mechanism

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:168,374,120...168,381,528

G

fibroblast growth factor 21

severity

mRNA:increased expression:liver (rat)

RGD

NCBI chr 1:105,219,825...105,221,376
Ensembl chr 1:96,083,441...96,090,454

G

Fms related receptor tyrosine kinase 1

CTD Direct Evidence: therapeutic

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626

G

flavin containing dimethylaniline monoxygenase 3

CTD Direct Evidence: therapeutic

NCBI chr13:77,838,899...77,868,869
Ensembl chr13:75,309,374...75,328,028

G

ferritin light chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:105,072,858...105,074,705
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725

G

glucose-6-phosphatase catalytic subunit 1

mRNA:decreased expression:liver (mouse)

RGD

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

treatment

RGD

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801

G

growth arrest and DNA-damage-inducible, alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115

G

glucosidase II alpha subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

GC, vitamin D binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr14:18,916,255...18,951,670
Ensembl chr14:18,632,135...18,667,567

G

glutamate-cysteine ligase, catalytic subunit

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19481141 PMID:17573345

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535

G

guanine deaminase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:228,333,401...228,408,901
Ensembl chr 1:218,906,815...218,982,416

G

GDP dissociation inhibitor 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:157,238,900...157,245,562
Ensembl chr X:152,087,444...152,094,272

G

growth factor, augmenter of liver regeneration

treatment

RGD

PMID:22033404 PMID:15968720

RGD:9685722, RGD:9685727

NCBI chr10:14,223,023...14,225,736
Ensembl chr10:13,718,489...13,720,869

G

gamma-glutamyl hydrolase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:38,326,747...38,349,655
Ensembl chr 5:33,529,880...33,552,787

G

gamma-glutamyltransferase 1

RGD

NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,700...13,108,442

G

ghrelin and obestatin prepropeptide

CTD Direct Evidence: therapeutic

NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:146,865,712...146,869,621

G

glutamate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:9,646,569...9,680,215
Ensembl chr16:9,640,312...9,673,957

G

glutamic-oxaloacetic transaminase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:242,357,306...242,380,633

G

glycerol-3-phosphate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:130,844,138...130,851,529

G

glutamic--pyruvic transaminase

treatment

CTD Direct Evidence: marker/mechanism
protein:increased expression, activity:serum:

CTD
RGD

PMID:145039 PMID:19481104 PMID:19085960 PMID:19085960 PMID:27293452 More...

RGD:14975249, RGD:14975249, RGD:14975168, RGD:14975166, RGD:14975162

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

glutamic--pyruvic transaminase 2

protein:increased expression, activity:serum:

RGD

PMID:19085960 PMID:19085960

RGD:14975249, RGD:14975249

NCBI chr19:37,700,023...37,734,551
Ensembl chr19:21,517,621...21,560,610

G

G protein-coupled receptor kinase 4

CTD Direct Evidence: marker/mechanism

NCBI chr14:80,230,699...80,305,292
Ensembl chr14:76,006,218...76,080,693

G

gelsolin

CTD Direct Evidence: marker/mechanism

NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:18,585,172...18,638,402

G

glutathione-disulfide reductase

treatment

mRNA, protein:increased expression:liver
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:25226513 PMID:28069987 PMID:23554813 PMID:24154663

RGD:7257532, RGD:10401878

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 4

CTD Direct Evidence: marker/mechanism

NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase mu 1

no_association

CTD Direct Evidence: marker/mechanism
protein:increased expression:liver

CTD
RGD

PMID:17465707 PMID:18666253 PMID:25501156 PMID:24465778 PMID:24903797 More...

RGD:14700970, RGD:14700959, RGD:14700941, RGD:14700937, RGD:7241599

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:198,312,179...198,316,962
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase mu 4

CTD Direct Evidence: marker/mechanism

NCBI chr 2:198,356,114...198,373,487
Ensembl chr 2:195,680,004...195,685,323

G

glutathione S-transferase, mu 5

CTD Direct Evidence: therapeutic

NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase omega 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:246,721,221...246,731,468

G

glutathione S-transferase pi 1

CTD Direct Evidence: marker/mechanism

PMID:20623750 PMID:25226513

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

CTD Direct Evidence: marker/mechanism

PMID:18397238 PMID:18666253 PMID:25226513

NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,669...12,873,585

G

H19 imprinted maternally expressed transcript

CTD Direct Evidence: marker/mechanism

NCBI chr 1:207,160,175...207,162,851
Ensembl chr 1:197,730,698...197,733,134

G

H2A.X variant histone

treatment

RGD

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

2-hydroxyacyl-CoA lyase 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:6,831,293...6,869,410
Ensembl chr16:6,824,906...6,863,027

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:26,187,956...26,227,869

G

hepcidin antimicrobial peptide

mRNA:increased expression:hepatocyte

RGD

NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:86,170,901...86,172,891

G

hydroxyacid oxidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:188,888,848...188,921,567
Ensembl chr 2:186,200,504...186,224,425

G

hepatitis A virus cellular receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698

G

hemoglobin alpha, adult chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:15,841,724...15,842,580
Ensembl chr10:15,307,815...15,338,392

G

high mobility group box 1

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19783637 PMID:29091898

NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

treatment

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:18227147 PMID:22688006 PMID:22886620 PMID:29091898

RGD:10762620, RGD:15090820

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

4-hydroxyphenylpyruvate dioxygenase

CTD Direct Evidence: marker/mechanism

PMID:16099942 PMID:22872058

NCBI chr12:39,042,246...39,053,596
Ensembl chr12:33,381,231...33,392,766

G

hypoxanthine phosphoribosyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:137,655,744...137,687,718
Ensembl chr X:132,736,096...132,768,154

G

hemopexin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:159,932,755...159,940,328

G

histamine receptor H 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:10,371,083...10,412,979
Ensembl chr17:10,368,298...10,407,631

G

heat shock protein family A (Hsp70) member 5

CTD Direct Evidence: marker/mechanism

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

protein:altered localization:liver (rat)

RGD

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259

G

intercellular adhesion molecule 1

treatment

RGD

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

isocitrate dehydrogenase (NADP(+)) 2

severity

RGD

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025

G

indoleamine 2,3-dioxygenase 2

CTD Direct Evidence: marker/mechanism

NCBI chr16:74,161,761...74,200,651
Ensembl chr16:67,459,190...67,496,324

G

interferon gamma

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12153990 PMID:21245496 PMID:30013034

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

CTD Direct Evidence: marker/mechanism

PMID:23639586 PMID:25226513

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 11

CTD Direct Evidence: therapeutic

NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 12B

CTD Direct Evidence: therapeutic

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903

G

interleukin 17A

CTD Direct Evidence: marker/mechanism

PMID:19633216 PMID:24949944

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 18

CTD Direct Evidence: marker/mechanism

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

CTD Direct Evidence: therapeutic

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

treatment

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:19164858 PMID:28138970 PMID:23102243 PMID:29091898 PMID:31342809 More...

RGD:7204421, RGD:15090820, RGD:15036799, RGD:14975281, RGD:13793380

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 22

CTD Direct Evidence: therapeutic

PMID:15122762 PMID:16212920 PMID:23375450

NCBI chr 7:55,687,061...55,691,526
Ensembl chr 7:53,801,206...53,806,186

G

interleukin 4

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:21094227 PMID:21735453 PMID:22107450

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

treatment

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:7532385 PMID:15763341 PMID:29091898

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

inner membrane mitochondrial protein

CTD Direct Evidence: marker/mechanism

NCBI chr 4:105,438,657...105,477,370
Ensembl chr 4:103,880,459...103,919,109

G

interleukin-1 receptor-associated kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:156,919,927...156,929,825
Ensembl chr X:151,768,777...151,778,521

G

inositol 1,4,5-trisphosphate receptor, type 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:141,187,418...141,510,491

G

JunD proto-oncogene, AP-1 transcription factor subunit

CTD Direct Evidence: marker/mechanism

NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,734,122...18,735,799

G

Kelch-like ECH-associated protein 1

RGD

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862

G

KIT ligand

CTD Direct Evidence: therapeutic

NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:34,896,053...34,977,214

G

kininogen 1

CTD Direct Evidence: marker/mechanism

PMID:20362651 PMID:30685357

NCBI chr11:91,317,354...91,340,148
Ensembl chr11:77,812,752...77,835,555

G

keratin 18

mRNA, protein:increased expression:liver (mouse)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19783637 PMID:33483742 PMID:38521541 PMID:17340120

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

keratin 8

CTD Direct Evidence: marker/mechanism

NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:133,124,203...133,131,728

G

leucine aminopeptidase 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:69,820,907...69,839,891
Ensembl chr14:65,608,376...65,627,359

G

lipopolysaccharide binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:146,954,015...146,981,586

G

lecithin cholesterol acyltransferase

mRNA:decreased expression:liver (rat)

RGD

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

PMID:20362651 PMID:20623750

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095

G

low density lipoprotein receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580

G

galectin 3

CTD Direct Evidence: marker/mechanism

NCBI chr15:23,099,795...23,111,731
Ensembl chr15:20,607,692...20,632,025

G

lipase C, hepatic type

mRNA:decreased expression:liver (rat)

RGD

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipoprotein lipase

treatment

RGD

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249

G

lecithin retinol acyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:170,562,148...170,571,212
Ensembl chr 2:168,266,877...168,273,619

G

leukotriene B4 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr15:33,233,120...33,235,636

G

lactotransferrin

CTD Direct Evidence: therapeutic

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:110,999,948...111,022,795

G

microtubule-associated protein 1 light chain 3 beta

CTD Direct Evidence: marker/mechanism

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 5

CTD Direct Evidence: marker/mechanism

NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:14,685,492...14,904,800

G

methionine adenosyltransferase 1A

CTD Direct Evidence: marker/mechanism

NCBI chr16:17,017,168...17,035,368
Ensembl chr16:16,983,022...17,001,274

G

methylcrotonyl-CoA carboxylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:120,727,313...120,779,334
Ensembl chr 2:118,799,150...118,851,222

G

malate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:99,831,934...99,847,227
Ensembl chr14:95,630,306...95,645,925

G

malic enzyme 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:87,549,043...87,660,304

G

mediator complex subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:83,641,851...83,685,560
Ensembl chr10:83,145,568...83,189,299

G

microRNA 100

CTD Direct Evidence: marker/mechanism

NCBI chr 8:50,798,295...50,798,374
Ensembl chr 8:41,901,225...41,901,304

G

microRNA 103a-1

CTD Direct Evidence: marker/mechanism

NCBI chr10:20,748,474...20,748,559
Ensembl chr10:20,244,412...20,244,497

G

microRNA 106b

miRNA:decreased expression:liver (rat)
DNA:hypermethylation:promoter

RGD

PMID:29554950 PMID:29554950

RGD:15042854, RGD:15042854

NCBI chr12:22,157,053...22,157,134
Ensembl chr12:17,043,344...17,043,425

G

microRNA 107

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr 1:241,750,418...241,750,504
Ensembl chr 1:232,337,767...232,337,853

G

microRNA 10a

CTD Direct Evidence: marker/mechanism

NCBI chr10:81,779,709...81,779,818
Ensembl chr10:81,283,171...81,283,280

G

microRNA 10b

CTD Direct Evidence: marker/mechanism

NCBI chr 3:80,035,859...80,035,967
Ensembl chr 3:59,628,438...59,628,546

G

microRNA 122

CTD Direct Evidence: marker/mechanism

PMID:22045675 PMID:22363424 PMID:25359176 PMID:25527335 PMID:26489516 More...

NCBI chr18:61,028,817...61,028,901

G

microRNA 1249

CTD Direct Evidence: marker/mechanism

NCBI chr 7:116,075,593...116,075,712
Ensembl chr 7:116,075,593...116,075,712

G

microRNA 125b-1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:50,850,036...50,850,122
Ensembl chr 8:41,952,966...41,953,052

G

microRNA 125b-2

CTD Direct Evidence: marker/mechanism

NCBI chr11:29,732,572...29,732,659

G

microRNA 1306

CTD Direct Evidence: marker/mechanism

NCBI chr11:96,213,960...96,214,032
Ensembl chr11:82,709,637...82,709,719

G

microRNA 130a

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr 3:90,229,228...90,229,315
Ensembl chr 3:69,822,542...69,822,629

G

microRNA 130b

CTD Direct Evidence: marker/mechanism

NCBI chr11:97,384,380...97,384,461
Ensembl chr11:83,880,163...83,880,244

G

microRNA 132

CTD Direct Evidence: marker/mechanism

NCBI chr10:60,522,033...60,522,133
Ensembl chr10:60,023,696...60,023,796

G

microRNA 141

CTD Direct Evidence: marker/mechanism

PMID:22363424 PMID:28545106

NCBI chr 4:159,209,525...159,209,618
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 142

CTD Direct Evidence: marker/mechanism

NCBI chr10:73,055,104...73,055,190
Ensembl chr10:72,557,857...72,557,967

G

microRNA 143

CTD Direct Evidence: marker/mechanism

NCBI chr18:57,371,349...57,371,453
Ensembl chr18:55,101,006...55,101,110

G

microRNA 148a

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr 4:81,664,431...81,664,527
Ensembl chr 4:80,333,762...80,333,858

G

microRNA 150

CTD Direct Evidence: marker/mechanism

NCBI chr 1:104,741,487...104,741,571
Ensembl chr 1:95,605,024...95,605,108

G

microRNA 151b

CTD Direct Evidence: marker/mechanism

NCBI chr 7:105,172,377...105,172,496
Ensembl chr 7:105,172,377...105,172,496

G

microRNA 152

CTD Direct Evidence: marker/mechanism

NCBI chr10:82,329,383...82,329,467
Ensembl chr10:81,832,936...81,833,020

G

microRNA 155

treatment

RGD

PMID:29420849 PMID:26867493 PMID:27673475

RGD:21409750, RGD:25671474, RGD:25671463

NCBI chr11:37,261,114...37,261,178
Ensembl chr11:23,774,654...23,774,718

G

microRNA 17

CTD Direct Evidence: marker/mechanism

NCBI chr15:98,587,848...98,587,931
Ensembl chr15:92,180,629...92,180,712

G

microRNA 181c

CTD Direct Evidence: marker/mechanism

NCBI chr19:40,888,291...40,888,396
Ensembl chr19:23,983,523...23,983,628

G

microRNA 188

CTD Direct Evidence: marker/mechanism

NCBI chr X:17,919,585...17,919,664
Ensembl chr X:15,247,715...15,247,794

G

microRNA 18a

CTD Direct Evidence: marker/mechanism

NCBI chr15:98,587,984...98,588,079
Ensembl chr15:92,180,765...92,180,860

G

microRNA 191

CTD Direct Evidence: marker/mechanism

NCBI chr 8:118,142,627...118,142,717

G

microRNA 192

CTD Direct Evidence: marker/mechanism

PMID:22045675 PMID:25359176 PMID:28483554 PMID:28545106

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

microRNA 193a

CTD Direct Evidence: marker/mechanism

NCBI chr10:65,170,306...65,170,417
Ensembl chr10:64,672,343...64,672,454

G

microRNA 193b

CTD Direct Evidence: marker/mechanism

NCBI chr10:1,317,742...1,317,824
Ensembl chr10:1,317,742...1,317,824

G

microRNA 194-1

CTD Direct Evidence: marker/mechanism

NCBI chr13:99,382,716...99,382,798
Ensembl chr13:96,851,166...96,851,248

G

microRNA 19a

CTD Direct Evidence: marker/mechanism

NCBI chr15:98,588,131...98,588,212
Ensembl chr15:92,180,912...92,180,993

G

microRNA 1a-1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:167,487,117...167,487,201
Ensembl chr 3:167,487,117...167,487,201

G

microRNA 200c

CTD Direct Evidence: marker/mechanism

NCBI chr 4:159,209,965...159,210,033

G

microRNA 203-2

CTD Direct Evidence: therapeutic

NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656

G

microRNA 21

CTD Direct Evidence: marker/mechanism

NCBI chr10:71,902,600...71,902,691
Ensembl chr10:71,405,257...71,405,348

G

microRNA 210

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,755,923...205,756,032
Ensembl chr 1:196,326,337...196,326,454

G

microRNA 217

CTD Direct Evidence: marker/mechanism

NCBI chr14:106,732,485...106,732,589
Ensembl chr14:102,531,505...102,531,609

G

microRNA 22

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr10:60,805,331...60,805,425
Ensembl chr10:60,307,039...60,307,133

G

microRNA 221

CTD Direct Evidence: marker/mechanism

NCBI chr X:6,023,182...6,023,290
Ensembl chr X:3,429,465...3,429,573

G

microRNA 222

CTD Direct Evidence: marker/mechanism

NCBI chr X:6,022,621...6,022,723
Ensembl chr X:3,428,904...3,429,006

G

microRNA 223

RNA:increased expression:serum,liver

RGD

NCBI chr X:65,151,383...65,151,492
Ensembl chr X:61,141,887...61,141,996

G

microRNA 23a

CTD Direct Evidence: marker/mechanism

NCBI chr19:40,859,769...40,859,843
Ensembl chr19:23,954,997...23,955,071

G

microRNA 23b

CTD Direct Evidence: marker/mechanism

NCBI chr17:1,819,386...1,819,482
Ensembl chr17:1,813,667...1,813,763

G

microRNA 27b

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr17:1,819,147...1,819,243
Ensembl chr17:1,813,426...1,813,529

G

microRNA 29b-2

CTD Direct Evidence: marker/mechanism

NCBI chr13:109,098,831...109,098,911
Ensembl chr13:106,570,367...106,570,456

G

microRNA 301a

CTD Direct Evidence: marker/mechanism

NCBI chr10:72,422,599...72,422,698
Ensembl chr10:71,925,336...71,925,435

G

microRNA 30a

CTD Direct Evidence: marker/mechanism

PMID:22363424 PMID:25359176 PMID:28545106

NCBI chr 9:33,233,941...33,234,011
Ensembl chr 9:25,737,600...25,737,670

G

microRNA 30b

CTD Direct Evidence: marker/mechanism

NCBI chr 7:102,021,543...102,021,629
Ensembl chr 7:100,132,589...100,132,675

G

microRNA 30c-1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:139,634,455...139,634,543
Ensembl chr 5:134,349,237...134,349,325

G

microRNA 320a

CTD Direct Evidence: marker/mechanism

PMID:28545106 PMID:30125006

NCBI chr15:51,926,088...51,926,169
Ensembl chr15:45,516,392...45,516,473

G

microRNA 328

CTD Direct Evidence: marker/mechanism

NCBI chr19:50,094,691...50,094,774
Ensembl chr19:33,184,766...33,184,849

G

microRNA 337

CTD Direct Evidence: marker/mechanism

NCBI chr 6:134,321,142...134,321,238
Ensembl chr 6:128,538,902...128,538,998

G

microRNA 342

CTD Direct Evidence: marker/mechanism

NCBI chr 6:133,329,655...133,329,753
Ensembl chr 6:127,565,269...127,565,367

G

microRNA 345

CTD Direct Evidence: marker/mechanism

NCBI chr 6:133,518,403...133,518,498
Ensembl chr 6:127,754,027...127,754,122

G

microRNA 34a

CTD Direct Evidence: marker/mechanism

NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:160,533,002...160,533,103

G

microRNA 34c

CTD Direct Evidence: marker/mechanism

NCBI chr 8:60,306,091...60,306,167
Ensembl chr 8:51,409,726...51,409,802

G

microRNA 361

CTD Direct Evidence: marker/mechanism

NCBI chr X:82,438,463...82,438,532
Ensembl chr X:78,246,206...78,246,275

G

microRNA 410

CTD Direct Evidence: marker/mechanism

NCBI chr 6:134,579,763...134,579,838
Ensembl chr 6:128,758,354...128,758,434

G

microRNA 423

CTD Direct Evidence: marker/mechanism

NCBI chr10:62,412,272...62,412,350
Ensembl chr10:61,914,133...61,914,226

G

microRNA 455

CTD Direct Evidence: marker/mechanism

NCBI chr 5:81,704,834...81,704,911
Ensembl chr 5:76,689,313...76,689,390

G

microRNA 484

CTD Direct Evidence: marker/mechanism

NCBI chr10:1,394,905...1,394,981
Ensembl chr10:887,684...887,760

G

microRNA 497

CTD Direct Evidence: marker/mechanism

NCBI chr10:55,450,171...55,450,239
Ensembl chr10:54,951,505...54,951,584

G

microRNA 499a

CTD Direct Evidence: marker/mechanism

NCBI chr 3:144,110,469...144,110,533
Ensembl chr 3:144,110,469...144,110,533

G

microRNA 503

CTD Direct Evidence: marker/mechanism

NCBI chr X:137,725,856...137,725,926
Ensembl chr X:132,806,303...132,806,373

G

microRNA 532

CTD Direct Evidence: marker/mechanism

NCBI chr X:17,919,185...17,919,263
Ensembl chr X:15,247,315...15,247,393

G

microRNA 592

CTD Direct Evidence: marker/mechanism

PMID:22363424 PMID:28545106

NCBI chr 4:56,505,280...56,505,375
Ensembl chr 4:56,505,280...56,505,375

G

microRNA 764

CTD Direct Evidence: marker/mechanism

NCBI chr X:110,678,597...110,678,704
Ensembl chr X:110,678,597...110,678,704

G

microRNA 877

CTD Direct Evidence: marker/mechanism

NCBI chr20:2,816,284...2,816,368
Ensembl chr20:2,811,476...2,811,560

G

microRNA 93

CTD Direct Evidence: marker/mechanism

NCBI chr12:22,156,844...22,156,930
Ensembl chr12:17,043,135...17,043,221

G

microRNA 99a

CTD Direct Evidence: marker/mechanism

NCBI chr11:29,687,392...29,687,472
Ensembl chr11:16,200,443...16,200,523

G

microRNA let-7b

CTD Direct Evidence: marker/mechanism

PMID:28545106 PMID:30125006

NCBI chr 7:118,684,038...118,684,122
Ensembl chr 7:116,804,186...116,804,270

G

microRNA let-7c-1

CTD Direct Evidence: marker/mechanism

NCBI chr11:29,688,112...29,688,205
Ensembl chr11:16,201,158...16,201,265

G

microRNA let-7d

CTD Direct Evidence: marker/mechanism

NCBI chr17:16,322,260...16,322,357
Ensembl chr17:16,115,893...16,115,990

G

microRNA let-7g

CTD Direct Evidence: marker/mechanism

NCBI chr 8:115,701,020...115,701,107
Ensembl chr 8:106,822,280...106,822,388

G

microRNA let-7i

CTD Direct Evidence: marker/mechanism

NCBI chr 7:60,527,877...60,527,961
Ensembl chr 7:58,642,480...58,642,571

G

matrix metallopeptidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

CTD Direct Evidence: marker/mechanism

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120

G

macrophage stimulating 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:117,646,485...117,652,016
Ensembl chr 8:108,768,839...108,773,416

G

macrophage stimulating 1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:117,471,928...117,491,059
Ensembl chr 8:108,597,299...108,612,455

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

mRNA:decreased expression:blood

RGD

NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

methylenetetrahydrofolate reductase

treatment

CTD Direct Evidence: marker/mechanism
associated with precursor lymphoblastic lymphoma/leukemia; DNA:SNP: :677C>T(human)

CTD
RGD

PMID:18551038 PMID:19648163 PMID:30545275

NCBI chr 5:163,748,346...163,768,141
Ensembl chr 5:158,465,296...158,483,797

G

myotrophin

CTD Direct Evidence: marker/mechanism

NCBI chr 4:65,126,390...65,153,803
Ensembl chr 4:64,157,641...64,186,724

G

murinoglobulin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:156,836,140...156,908,972
Ensembl chr 4:155,164,011...155,236,475

G

MYD88, innate immune signal transduction adaptor

ameliorates

RGD

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415

G

N-acetyltransferase 2

treatment

associated with Tuberculosis;DNA:haplotype: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11915035 PMID:16799928 PMID:17950035 PMID:25693865 PMID:18023090

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520

G

NADH:ubiquinone oxidoreductase core subunit S3

CTD Direct Evidence: marker/mechanism

NCBI chr 3:97,332,477...97,339,654
Ensembl chr 3:76,876,646...76,883,824

G

nuclear factor of activated T-cells 4

CTD Direct Evidence: therapeutic

NCBI chr15:33,256,912...33,284,522
Ensembl chr15:29,305,535...29,314,610

G

NFE2 like bZIP transcription factor 2

treatment

induced by methotrexate (CHEBI:44185), treated by ferulic acid (CHEBI:17620)
CTD Direct Evidence: therapeutic

CTD
RGD

PMID:22491424 PMID:22627062 PMID:24813929 PMID:26958860 PMID:30215777 More...

RGD:6893370, RGD:21201308, RGD:21201305, RGD:21201283, RGD:21201280, RGD:15090820

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

treatment
susceptibility

associated with tuberculosis ;DNA:SNPs,haplotypes: 3'utr,5'utr: (rs78872571,rs4647992) (human)

RGD

PMID:29091898 PMID:31490979

RGD:15090820, RGD:40902984

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

nuclear transcription factor, X-box binding-like 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498

G

NME/NM23 nucleoside diphosphate kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:79,394,999...79,400,418
Ensembl chr10:78,897,770...78,903,538
Ensembl chr20:78,897,770...78,903,538

G

notch receptor 1

CTD Direct Evidence: therapeutic

NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:140,901,097...141,077,406

G

NAD(P)H quinone dehydrogenase 1

treatment

RGD

PMID:28522909 PMID:29091898 PMID:28472605

RGD:13439737, RGD:15090820, RGD:13439739

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

CTD Direct Evidence: therapeutic

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group D, member 1

treatment

RGD

NCBI chr10:84,224,599...84,231,812
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group H, member 3

CTD Direct Evidence: therapeutic

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

treatment
severity

CTD Direct Evidence: marker/mechanism
mRNA:decreased expression:liver (rat)
protein:decreased expression:liver (rat)

CTD
RGD

PMID:12875239 PMID:29091898 PMID:28827769 PMID:30068870 PMID:22711662 More...

RGD:15090820, RGD:15045609, RGD:15042870, RGD:14701036, RGD:14701035

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

susceptibility

CTD Direct Evidence: marker/mechanism|therapeutic
associated with tuberculosis ;DNA:SNP,haplotypes:promoter: (rs3814055) (human)

CTD
RGD

PMID:19797606 PMID:28058446 PMID:31490979

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:14742670 PMID:25656644 PMID:28058446

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 2, group F, member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:124,009,181...124,022,031

G

nuclear receptor subfamily 5, group A, member 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:50,865,253...50,985,107
Ensembl chr13:48,316,301...48,433,326

G

neuronal regeneration related protein

CTD Direct Evidence: marker/mechanism

NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,017,083...25,046,591

G

netrin 1

CTD Direct Evidence: therapeutic

NCBI chr10:53,398,852...53,597,595
Ensembl chr10:52,899,934...53,085,326

G

NUS1 dehydrodolichyl diphosphate synthase subunit

CTD Direct Evidence: therapeutic

NCBI chr20:32,354,519...32,381,265
Ensembl chr20:31,811,817...31,838,561

G

alpha-2u globulin PGCL4

CTD Direct Evidence: marker/mechanism

NCBI chr 5:74,842,316...74,845,858
Ensembl chr 5:74,842,316...74,845,757

G

OCIA domain containing 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:34,897,851...34,915,291
Ensembl chr14:34,897,847...34,915,286

G

oxoglutarate dehydrogenase

CTD Direct Evidence: marker/mechanism

NCBI chr14:85,363,949...85,431,405
Ensembl chr14:81,150,091...81,217,479

G

olfactory receptor 59

CTD Direct Evidence: marker/mechanism

NCBI chr 1:166,604,972...166,639,634
Ensembl chr 1:157,193,080...157,211,179

G

prolyl 4-hydroxylase subunit beta

CTD Direct Evidence: marker/mechanism

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:105,836,982...105,848,500

G

phenylalanine hydroxylase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:23,793,096...23,885,631
Ensembl chr 7:21,933,179...21,998,130

G

poly(A) specific ribonuclease subunit PAN2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:1,313,654...1,332,252
Ensembl chr 7:729,562...747,744

G

Pannexin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:11,850,730...11,889,774

G

Parkinsonism associated deglycase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:161,353,719...161,376,970

G

pyruvate carboxylase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:211,228,708...211,327,792
Ensembl chr 1:201,804,267...201,898,380

G

procollagen C-endopeptidase enhancer

CTD Direct Evidence: marker/mechanism

NCBI chr12:24,720,972...24,727,287
Ensembl chr12:19,084,210...19,090,508

G

phosphate cytidylyltransferase 1A, choline

CTD Direct Evidence: marker/mechanism

NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357

G

pyruvate dehydrogenase kinase 4

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:21182459 PMID:31809757

NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:33,589,799...33,601,850

G

PDZ and LIM domain 5

CTD Direct Evidence: marker/mechanism

NCBI chr 2:233,625,478...233,793,582
Ensembl chr 2:230,952,248...231,120,275

G

peroxisomal biogenesis factor 11 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 1:143,089,410...143,096,491
Ensembl chr 1:133,680,091...133,687,172

G

phosphoglucomutase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:119,710,734...119,770,159
Ensembl chr 5:114,595,293...114,654,728

G

plasminogen activator, tissue type

CTD Direct Evidence: marker/mechanism

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223

G

plasminogen

CTD Direct Evidence: marker/mechanism

NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:48,325,185...48,367,786

G

plastin 3

CTD Direct Evidence: marker/mechanism

NCBI chr X:116,401,247...116,495,898
Ensembl chr X:111,589,254...111,683,891

G

purine nucleoside phosphorylase

CTD Direct Evidence: marker/mechanism

NCBI chr15:26,644,147...26,651,808
Ensembl chr15:24,170,602...24,203,986

G

proline-rich nuclear receptor coactivator 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161

G

DNA polymerase gamma, catalytic subunit

susceptibility
no_association

CTD Direct Evidence: marker/mechanism
DNA:missense mutation:cds:p.W748S, p.E1143G (2243G>C, 3428A>G) (human)
DNA:missense mutations:cds:p.Q1236H, p.E1143G (33708G>T, 3428A>G) (human)

CTD
RGD

PMID:18208989 PMID:20138553 PMID:25065347 PMID:30255931

RGD:15039302, RGD:15039297

NCBI chr 1:142,792,119...142,808,933
Ensembl chr 1:133,382,766...133,398,567

G

RNA polymerase II subunit G

CTD Direct Evidence: marker/mechanism

NCBI chr 1:215,118,278...215,125,389
Ensembl chr 1:205,689,160...205,692,686

G

paraoxonase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

LPS-induced acute liver damage
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:24385052 PMID:38181850 PMID:21262334

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

mRNA, protein:decreased expression:liver

RGD

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase targeting COQ7

CTD Direct Evidence: marker/mechanism

NCBI chr12:39,910,728...39,949,101
Ensembl chr12:34,249,977...34,288,339

G

protein kinase AMP-activated catalytic subunit alpha 1

treatment

RGD

NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase C, delta

CTD Direct Evidence: therapeutic

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,769,215...5,799,352

G

protein kinase, DNA-activated, catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr11:98,544,952...98,762,499
Ensembl chr11:85,040,792...85,257,952

G

pancreas associated transcription factor 1a

CTD Direct Evidence: therapeutic

NCBI chr17:86,959,621...86,961,475
Ensembl chr17:82,051,281...82,053,135

G

prostaglandin E synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:36,088,246...36,095,430
Ensembl chr 3:15,690,501...15,697,688

G

prostaglandin-endoperoxide synthase 2

treatment

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:11743745 PMID:29091898

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

pumilio RNA-binding family member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:148,120,712...148,238,468
Ensembl chr 5:142,837,127...142,954,039

G

glycogen phosphorylase L

CTD Direct Evidence: marker/mechanism
protein:increased expression:serum (rat)

CTD
RGD

PMID:25231249 PMID:25336395

NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:88,697,593...88,740,310

G

RAS p21 protein activator 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:15,857,980...15,940,854

G

retinol binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:99,025,206...99,046,743

G

retinol dehydrogenase 13

CTD Direct Evidence: marker/mechanism

NCBI chr 1:78,415,765...78,444,116
Ensembl chr 1:69,373,113...69,400,908

G

receptor accessory protein 5

CTD Direct Evidence: marker/mechanism

NCBI chr18:26,219,528...26,257,505
Ensembl chr18:25,945,381...25,976,509

G

regucalcin

CTD Direct Evidence: marker/mechanism

NCBI chr X:4,172,537...4,190,112
Ensembl chr X:1,619,032...1,634,450

G

receptor-interacting serine-threonine kinase 3

CTD Direct Evidence: therapeutic
protein:increased expression:liver (mouse)

CTD
RGD

PMID:26769846 PMID:28205631

NCBI chr15:33,253,071...33,262,025
Ensembl chr15:29,283,145...29,292,121

G

RT1 class II, locus Ba

susceptibility

DNA:polymorphism: :HLA-DQA1*0102(human)
associated with tuberculosis;DNA:polymorphism: :HLA-DQA1*0102(human)

RGD

PMID:20639878 PMID:12359646

RGD:14398844, RGD:14401573

NCBI chr20:4,577,057...4,581,650
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:polymorphism: :HLA-DQB1*05(human)
DNA:polymorphism, haplotype

CTD
RGD

PMID:21570397 PMID:25250564 PMID:26959717

RGD:36174016, RGD:11573514

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597

G

RT1 class I, locus CE16

CTD Direct Evidence: marker/mechanism

PMID:21570397 PMID:28043905

NCBI chr20:3,261,656...3,265,548
Ensembl chr20:3,257,123...3,279,563

G

RT1 class II, locus Db1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,548,666...4,558,258

G

S100 calcium binding protein A11

CTD Direct Evidence: marker/mechanism

NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:179,191,715...179,197,044

G

scavenger receptor class B, member 1

mRNA:increased expression:liver (rat)

RGD

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647

G

selenium binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:182,493,978...182,504,594

G

semaphorin 3A

CTD Direct Evidence: therapeutic

NCBI chr 4:22,239,418...22,709,907
Ensembl chr 4:21,287,982...21,494,432

G

semaphorin 4A

CTD Direct Evidence: marker/mechanism

NCBI chr 2:176,194,248...176,215,752
Ensembl chr 2:173,896,439...173,914,442

G

SUMO specific peptidase 2

CTD Direct Evidence: therapeutic

NCBI chr11:92,487,259...92,522,795
Ensembl chr11:78,981,432...79,018,238

G

serpin family A member 1

susceptibility

protein:decreased expression:plasma
DNA:missense mutation:cds:p.E264V(human)

RGD

PMID:11140575 PMID:20170533

RGD:1643168, RGD:14695048

NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:122,866,312...122,888,339

G

serpin family A member 6

CTD Direct Evidence: marker/mechanism

NCBI chr 6:128,544,828...128,555,064
Ensembl chr 6:122,780,043...122,790,349

G

serpin family E member 1

treatment

associated with precursor lymphoblastic lymphoma/leukemia;DNA:SNPs: :DNA:SNPs: :677C>T, 1298A>C(human)

RGD

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657

G

serpin family G member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:69,842,739...69,852,034

G

sestrin 2

CTD Direct Evidence: therapeutic

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:144,701,530...144,721,260

G

SAGA complex associated factor 29

CTD Direct Evidence: marker/mechanism

NCBI chr 1:190,668,803...190,702,500
Ensembl chr 1:181,238,468...181,274,781

G

SHC adaptor protein 1

CTD Direct Evidence: marker/mechanism

PMID:25231249 PMID:32659284

NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:174,837,930...174,849,536

G

solute carrier family 10 member 1

mRNA:decreased expression:liver (rat)

RGD

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 10, member 7

CTD Direct Evidence: marker/mechanism

NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464

G

solute carrier family 13 member 4

CTD Direct Evidence: marker/mechanism

NCBI chr 4:64,910,505...64,955,986
Ensembl chr 4:63,943,395...63,988,857

G

solute carrier family 22 member 8

CTD Direct Evidence: marker/mechanism

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25 member 29

CTD Direct Evidence: marker/mechanism

NCBI chr 6:133,506,403...133,517,322
Ensembl chr 6:127,742,033...127,752,940

G

solute carrier family 7 member 5

treatment

RGD

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:49,935,220...49,963,823

G

secretory leukocyte peptidase inhibitor

CTD Direct Evidence: marker/mechanism

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:153,082,369...153,084,453

G

sorting nexin 18

CTD Direct Evidence: marker/mechanism

NCBI chr 2:45,232,325...45,258,345
Ensembl chr 2:45,232,325...45,258,345

G

superoxide dismutase 1

CTD Direct Evidence: marker/mechanism

PMID:20623750 PMID:27349771

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

treatment
severity
susceptibility

CTD Direct Evidence: marker/mechanism
associated with acute lymphoblastic leukemia;DNA:SNP: :(rs4880)(human)
DNA:SNP:cds:p.Val16Ala(human)

CTD
RGD

PMID:25226513 PMID:27019981 PMID:19647030 PMID:19332662 PMID:20578157

RGD:11060605, RGD:26923961, RGD:26923959, RGD:26923957

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

superoxide dismutase 3

CTD Direct Evidence: therapeutic

NCBI chr14:62,822,865...62,828,602
Ensembl chr14:58,609,958...58,615,990

G

sorbitol dehydrogenase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:109,184,676...109,216,133

G

sortilin related receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:51,238,713...51,401,458
Ensembl chr 8:42,341,704...42,504,513

G

spindlin family member 2A

CTD Direct Evidence: marker/mechanism

NCBI chr X:20,847,871...20,849,854
Ensembl chr X:17,511,022...17,513,001

G

secreted phosphoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162

G

signal recognition particle 72

CTD Direct Evidence: marker/mechanism

NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729

G

signal transducer and activator of transcription 3

CTD Direct Evidence: therapeutic

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 4

severity

protein:increased phosphorylation:liver, inflammatory cell (mouse)
mRNA:increased expression:liver, macrophage (mouse)

RGD

PMID:24731448 PMID:23876342

RGD:25671417, RGD:25671422

NCBI chr 9:56,964,617...57,080,523
Ensembl chr 9:49,419,340...49,588,540

G

stimulator of interferon response cGAMP interactor 1

CTD Direct Evidence: therapeutic

NCBI chr18:27,606,196...27,612,544
Ensembl chr18:27,332,119...27,338,335

G

sulfotransferase family 1C member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:7,548,839...7,594,299
Ensembl chr 9:7,221,578...7,267,030

G

sulfotransferase family 1E member 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2B member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:105,336,614...105,397,744
Ensembl chr 1:96,200,156...96,261,295

G

sulfite oxidase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:1,687,666...1,691,759
Ensembl chr 7:1,103,151...1,107,038

G

transgelin 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:87,499,350...87,506,328
Ensembl chr13:84,967,009...84,973,972

G

transaldolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:196,493,589...196,503,974

G

thromboxane A2 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 7:9,034,077...9,041,489
Ensembl chr 7:8,383,378...8,388,176

G

tectonic family member 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:34,309,795...34,347,190
Ensembl chr12:34,309,897...34,342,267

G

transferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:103,767,995...103,816,511

G

transforming growth factor, beta 1

treatment

RGD

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:61,653,233...61,710,777

G

thrombospondin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:105,056,292...105,071,440

G

thrombopoietin

CTD Direct Evidence: therapeutic

Ensembl chr11:80,182,820...80,188,167

G

toll-like receptor 4

disease_progression

RGD

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628

G

toll-like receptor 5

CTD Direct Evidence: marker/mechanism

NCBI chr13:97,166,430...97,190,642
Ensembl chr13:94,634,801...94,657,738

G

toll-like receptor 9

severity
treatment

protein:increased expression: blood, neutrophil (human)

RGD

PMID:26457748 PMID:19164858 PMID:23509352

RGD:18337465, RGD:18337476, RGD:18337473

NCBI chr 8:115,743,407...115,747,523
Ensembl chr 8:106,864,680...106,868,796

G

transmembrane p24 trafficking protein 7

CTD Direct Evidence: marker/mechanism

NCBI chr18:41,505,167...41,512,243
Ensembl chr18:39,297,351...39,325,640

G

transmembrane protein 117

CTD Direct Evidence: marker/mechanism

NCBI chr 7:127,636,862...128,098,944
Ensembl chr 7:125,757,591...126,219,690

G

transmembrane protein 164

CTD Direct Evidence: marker/mechanism

NCBI chr X:111,084,830...111,245,419
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 38B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:73,255,662...73,291,383
Ensembl chr 5:68,460,304...68,496,025

G

tumor necrosis factor

treatment
severity

IDA
ISO
IEP
IMP

CTD Direct Evidence: marker/mechanism|therapeutic
protein:increased expression:serum (rat)

CTD
RGD

PMID:7532385 PMID:9696492 PMID:17709330 PMID:19638433 PMID:20623750 More...

RGD:10450531, RGD:15090820, RGD:15036799, RGD:14995485, RGD:14995437, RGD:14995435, RGD:14995432, RGD:14995429, RGD:14975281, RGD:14696804

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily M, member 2

RGD

NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,707,014...10,753,181

G

transthyretin

CTD Direct Evidence: marker/mechanism

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:11,943,789...11,951,008

G

tubulin, alpha 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 4B class IVb

CTD Direct Evidence: marker/mechanism

NCBI chr 3:28,435,999...28,438,455
Ensembl chr 3:8,037,799...8,040,296

G

ubiquitin-like modifier activating enzyme 5

CTD Direct Evidence: marker/mechanism

NCBI chr 8:113,544,037...113,559,711
Ensembl chr 8:104,665,046...104,680,894

G

UDP glucuronosyltransferase family 1 member A1

susceptibility

DNA:SNP:exon (rs4148323)(human)

RGD

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

CTD Direct Evidence: marker/mechanism

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

unc-93 homolog B1, TLR signaling regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 1:210,596,639...210,607,579
Ensembl chr 1:201,152,693...201,178,338

G

ubiquitin specific peptidase 5

CTD Direct Evidence: marker/mechanism

NCBI chr 4:159,305,927...159,321,345
Ensembl chr 4:157,619,643...157,634,711

G

integral membrane transport protein UST5r

CTD Direct Evidence: marker/mechanism

NCBI chr 1:214,640,172...214,716,024
Ensembl chr 1:205,211,034...205,286,718

G

vascular endothelial growth factor A

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:25231249 PMID:17784864

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

CTD Direct Evidence: marker/mechanism

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187

G

von Willebrand factor

protein:increased expression:liver:
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:28527913 PMID:7531171

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:158,360,152...158,491,539

G

WASP like actin nucleation promoting factor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:54,049,081...54,097,653
Ensembl chr 4:53,083,536...53,132,022

G

X-ray repair cross complementing 1

susceptibility

DNA:haploinsufficiency: : (mouse)

RGD

NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:80,141,207...80,168,701

G

xylulokinase

CTD Direct Evidence: marker/mechanism

NCBI chr 8:127,971,194...128,012,511
Ensembl chr 8:119,096,029...119,128,848

G

zinc finger DHHC-type palmitoyltransferase 23

CTD Direct Evidence: marker/mechanism

NCBI chr11:70,224,581...70,240,971
Ensembl chr11:56,718,826...56,734,194

Chemotherapy-Related Cognitive Impairment

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

advanced glycosylation end product-specific receptor

treatment

RGD

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,147,890...4,151,078

G

high mobility group box 1

treatment

RGD

NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

interleukin 1 beta

treatment

RGD

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

RELA proto-oncogene, NF-kB subunit

treatment

RGD

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

drug allergy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

angiotensin I converting enzyme

CTD Direct Evidence: marker/mechanism

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131

G

adenosine A1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,853...13,333,386

G

C-C motif chemokine ligand 11

CTD Direct Evidence: marker/mechanism

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 24

CTD Direct Evidence: marker/mechanism

NCBI chr12:26,737,423...26,741,420
Ensembl chr12:21,100,835...21,104,893

G

cysteinyl leukotriene receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:75,734,281...75,762,873
Ensembl chr X:71,663,821...71,690,121

G

cysteinyl leukotriene receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr15:54,599,043...54,638,314
Ensembl chr15:48,189,073...48,304,136

G

Fas ligand

CTD Direct Evidence: marker/mechanism

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215

G

Fc epsilon receptor Ia

CTD Direct Evidence: marker/mechanism

PMID:17125826 PMID:20485159

NCBI chr13:88,218,427...88,224,723
Ensembl chr13:85,686,092...85,692,351

G

Fc epsilon receptor Ig

CTD Direct Evidence: marker/mechanism

PMID:18534082 PMID:18595682

NCBI chr13:86,181,908...86,186,766
Ensembl chr13:83,649,449...83,671,443

G

glutathione S-transferase mu 1

susceptibility

DNA:deletion: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:11007341

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

susceptibility

associated with Acquired Immunodeficiency Syndrome;DNA:polymorphism:exon:A>G313 (rs1695) (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:16297214

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

susceptibility

DNA:deletion: :

RGD

NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,669...12,873,585

G

granzyme B

CTD Direct Evidence: marker/mechanism

NCBI chr15:34,459,007...34,462,469
Ensembl chr15:30,173,603...30,346,814

G

histamine N-methyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:26,978,274...27,010,291
Ensembl chr 3:6,591,463...6,624,012

G

heat shock protein family A (Hsp70) member 1A

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1 like

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,848,843...3,855,571

G

interleukin 10

CTD Direct Evidence: marker/mechanism

PMID:19222424 PMID:20485159

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

CTD Direct Evidence: marker/mechanism

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737

G

interleukin 2

RGD

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 4

CTD Direct Evidence: marker/mechanism

PMID:15867870 PMID:20485159

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:180,115,120...180,139,980

G

leukotriene C4 synthase

CTD Direct Evidence: marker/mechanism

NCBI chr10:35,060,002...35,066,466
Ensembl chr10:34,560,360...34,562,651

G

motilin

CTD Direct Evidence: marker/mechanism

NCBI chr20:5,304,249...5,308,948
Ensembl chr20:5,304,249...5,308,948

G

membrane spanning 4-domains A2

CTD Direct Evidence: marker/mechanism

PMID:16839402 PMID:18534082 PMID:20485159

NCBI chr 1:217,864,855...217,873,934
Ensembl chr 1:208,440,361...208,448,310

G

N-acetyltransferase 2

CTD Direct Evidence: marker/mechanism

PMID:20485159 PMID:20602614 PMID:21572414

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520

G

NLR family, pyrin domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811

G

periostin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:138,527,696...138,559,099

G

prostaglandin E receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin-endoperoxide synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:19,584,015...19,605,586

G

RT1 class II, locus Db1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,548,666...4,558,258

G

tachykinin, precursor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178

G

thromboxane A synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:68,631,841...68,803,959
Ensembl chr 4:67,665,007...67,837,096

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:11294926 PMID:20485159

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 10b

CTD Direct Evidence: marker/mechanism

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:44,840,386...44,867,467

Drug Eruptions

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:149,531,515...149,578,743

G

apolipoprotein A1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein C2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:88,457,397...88,462,365
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein C3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:46,531,478...46,533,583

G

brain-derived neurotrophic factor

mRNA:increased expression:lymph node, ear:

RGD

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

complement C4B

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,197,366...4,211,681

G

cytochrome P450, family 1, subfamily a, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily C, polypeptide 6

susceptibility
treatment

DNA:SNP: :Rs4244285(human)
associated with tuberculosis; DNA.polymorphism, haplotype:cds:p.W212X (human)

RGD

PMID:23551241 PMID:20941486

RGD:11352742, RGD:124713543

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023

G

Fc epsilon receptor Ia

CTD Direct Evidence: marker/mechanism

NCBI chr13:88,218,427...88,224,723
Ensembl chr13:85,686,092...85,692,351

G

interferon gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 17A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 18

CTD Direct Evidence: marker/mechanism

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

kininogen 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:1371395 PMID:3034372

NCBI chr11:91,317,354...91,340,148
Ensembl chr11:77,812,752...77,835,555

G

myeloperoxidase

CTD Direct Evidence: marker/mechanism

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819

G

methylenetetrahydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:163,748,346...163,768,141
Ensembl chr 5:158,465,296...158,483,797

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

RT1 class II, locus Ba

susceptibility

DNA:polymorphisms:exon:

RGD

NCBI chr20:4,577,057...4,581,650
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus Hb, pseudogene 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,777,494...4,781,486
Ensembl chr20:4,774,650...4,780,618

G

tachykinin, precursor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

transthyretin

CTD Direct Evidence: marker/mechanism

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:11,943,789...11,951,008

Drug Hypersensitivity Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

complement C1q A chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q B chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:154,402,276...154,407,827
Ensembl chr 5:149,118,846...149,124,407

G

complement C1q C chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:149,127,415...149,131,017

G

complement factor H-related 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:53,946,298...53,961,282
Ensembl chr13:51,369,211...51,410,592

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178

G

heat shock protein family A (Hsp70) member 1 like

DNA:polymorphism, haplotype: :p.M493T (human)

RGD

NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,848,843...3,855,571

G

interleukin 1 beta

DNA:SNP:promoter:-511C>T (rs 16944) (human)

RGD

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

DNA:SNP:intron:rs2234663 (human)

RGD

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:7,111,550...7,127,445

G

lipopolysaccharide binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:146,954,015...146,981,586

G

leucine-rich alpha-2-glycoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:1,034,691...1,036,937
Ensembl chr 9:947,516...949,813

G

orosomucoid 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:76,772,941...76,776,154

G

von Willebrand factor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:158,360,152...158,491,539

Drug-Induced Dyskinesia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

RGD

PMID:7740056 PMID:6445277

RGD:1598524, RGD:10047091

NCBI chr10:7,503,351...7,599,474
Ensembl chr10:6,999,819...7,092,835

G

calcium voltage-gated channel subunit alpha1 D

RGD

NCBI chr16:5,233,682...5,527,549
Ensembl chr16:5,228,306...5,668,215

G

catalase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

CTD Direct Evidence: therapeutic

NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:121,153,500...121,160,084

G

catechol-O-methyltransferase

RGD

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642

G

cytochrome P450, family 2, subfamily d, polypeptide 4

RGD

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759

G

drebrin 1

levodopainduced; protein:increased expression:striatum:

RGD

NCBI chr17:9,155,729...9,170,121
Ensembl chr17:9,150,659...9,164,984

G

dopa decarboxylase

associated with Parkinson Disease; protein:decreased expression:striatum (rat)

RGD

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:86,378,685...86,469,208

G

dopamine receptor D1

CTD Direct Evidence: marker/mechanism

PMID:7845605 PMID:10858612 PMID:16982285 PMID:19520364

NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:7845605 PMID:10534246 PMID:14629710 PMID:18707801

NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

CTD Direct Evidence: marker/mechanism

NCBI chr11:70,385,586...70,437,793
Ensembl chr11:56,879,689...56,940,596

G

early growth response 1

RGD

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766

G

FosB proto-oncogene, AP-1 transcription factor subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465

G

glutamate decarboxylase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:55,369,704...55,410,333

G

GTP cyclohydrolase 1

CTD Direct Evidence: therapeutic

NCBI chr15:22,884,006...22,917,412
Ensembl chr15:20,402,527...20,437,698

G

glial cell derived neurotrophic factor

CTD Direct Evidence: therapeutic

NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:56,895,010...56,917,209

G

glutamate-ammonia ligase

RGD

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:66,025,630...66,035,108

G

G protein-coupled receptor kinase 6

associated with Parkinson Disease

RGD

NCBI chr17:9,182,160...9,198,380
Ensembl chr17:9,177,019...9,192,644

G

glycogen synthase kinase 3 beta

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

homer scaffold protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:24,543,093...24,644,785

G

5-hydroxytryptamine receptor 1A

RGD

NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:36,694,174...36,695,442

G

microtubule-associated protein tau

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129

G

mechanistic target of rapamycin kinase

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311

G

prodynorphin

treatment
severity

CTD Direct Evidence: marker/mechanism
associated with Parkinsonism
associated with Parkinsonism;protein:increased expression:striatum

CTD
RGD

PMID:9767399 PMID:21737418 PMID:10869049 PMID:17884291 PMID:21737418

RGD:401900134, RGD:401851046, RGD:401850563

NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:116,900,992...116,913,334

G

proenkephalin

treatment
disease_progression

mRNA:increased expression:brain:striatum:
associated with Parkinsonism
associated with Parkinsonism;mRNA:increased expression:striatum
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:9767399 PMID:20456008 PMID:10869049 PMID:26113400

RGD:10003039, RGD:401900134, RGD:401851054

NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:17,183,806...17,189,129

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr10:83,843,948...83,853,063
Ensembl chr10:83,347,731...83,356,775

G

RAS protein-specific guanine nucleotide-releasing factor 1

CTD Direct Evidence: therapeutic

NCBI chr 8:99,324,986...99,454,099
Ensembl chr 8:90,445,154...90,574,269

G

RELA proto-oncogene, NF-kB subunit

protein:increased expression:nucleus, brain

RGD

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

regulator of G-protein signaling 4

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr13:84,469,593...84,475,884
Ensembl chr13:81,936,775...81,943,068

G

regulator of G-protein signaling 9

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:18160641 PMID:24663062

NCBI chr10:94,696,556...94,770,387
Ensembl chr10:94,197,054...94,270,892

G

tyrosine hydroxylase

CTD Direct Evidence: therapeutic

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767

Drug-Induced Enteropathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nitric oxide synthase 3

treatment

RGD

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166

drug-induced hepatitis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

susceptibility
no_association

DNA:polymorphisms,haplotype:promoter:g.-1774delG,g.-1549G>A(human)
DNA:SNPs:multiple:

RGD

PMID:17502832 PMID:22178260

RGD:14700816, RGD:14700817

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

cytochrome P450, family 2, subfamily e, polypeptide 1

DNA:hypermethylation:promoter

RGD

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023

G

3-hydroxy-3-methylglutaryl-CoA reductase

RGD

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703

G

lysophosphatidic acid receptor 1

protein:increased expression:liver (mouse)

RGD

NCBI chr 5:78,024,139...78,147,071
Ensembl chr 5:73,229,625...73,369,895

G

microRNA 22

in male; RNA:increased expression:liver:

RGD

NCBI chr10:60,805,331...60,805,425
Ensembl chr10:60,307,039...60,307,133

Efavirenz, Poor Metabolism of

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily b, polypeptide 3

susceptibility

ClinVar Annotator: match by term: Efavirenz, poor metabolism of

PMID:15194512 PMID:15622315 PMID:15668854 PMID:15825040 PMID:15864119 More...

NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143

erythema nodosum

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

complement C3

associated with Leprosy

RGD

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,087,437...2,114,429

G

complement factor B

associated with Leprosy

RGD

NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,951,474...3,976,505

G

glutathione S-transferase mu 1

susceptibility

associated with Behcet Syndrome;DNA:deletion:: (human)

RGD

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411

G

lymphotoxin alpha

associated with Sarcoidosis;DNA:polymorphism:intron

RGD

NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,618,853...3,620,859

G

RT1 class I, locus CE13

associated with Inflammatory Bowel Diseases; DNA:polymorphisms:cds:multiple (human)

RGD

NCBI chr20:3,314,491...3,322,815

G

tumor necrosis factor

susceptibility

associated with Inflammatory Bowel Diseases;DNA:polymorphisms: :-1031T>C(human)

RGD

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

vitamin D receptor

susceptibility

associated with Behcet Syndrome;DNA:polymorphism: : rs7975232(human)

RGD

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677

Halothane Hepatitis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamic--pyruvic transaminase

treatment

RGD

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

Hand-Foot Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

kinase insert domain receptor

treatment

DNA:polymorphism:cds:p.H472Q(human)

RGD

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,217,871...32,261,018

Metabolic Side Effects of Drugs and Substances

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

Associated with incense smoke exposure;mRNA:increased expression:heart (rat)

RGD

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

treatment

associated with nitrate tolerance
Associated with incense smoke exposure;mRNA:increased expression:heart (rat)
associated with nitrate tolerance; protein:decreased expression:thoracic aorta (rat)

RGD

PMID:16520233 PMID:25687613 PMID:12688525

RGD:401900296, RGD:401900684, RGD:401900656

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 3

susceptibility

DNA:SNP: :CYP2B6*6 (516G>T,785A>G) ((human)

RGD

NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143

G

myosin heavy chain 7

Associated with incense smoke exposure;mRNA:increased expression:heart (rat)

RGD

NCBI chr15:32,416,525...32,439,851
Ensembl chr15:28,446,550...28,468,217

G

natriuretic peptide A

Associated with incense smoke exposure;mRNA:increased expression:heart (rat)

RGD

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

Associated with incense smoke exposure;mRNA:increased expression:heart (rat)

RGD

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:158,416,866...158,418,168

Nakajo Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

proteasome 20S subunit beta 8

ClinVar Annotator: match by term: Nodular erythema digital changes

PMID:20159315 PMID:20534754 PMID:21129723 PMID:21953331 PMID:25741868 More...

NCBI chr20:4,654,068...4,657,049
Ensembl chr20:4,652,159...4,655,283

nephrotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

ameliorates

RGD

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

calcium voltage-gated channel subunit alpha1 G

treatment

RGD

NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,355,008...79,422,752

G

calcium voltage-gated channel subunit alpha1 S

treatment

RGD

NCBI chr13:50,045,668...50,115,903
Ensembl chr13:47,493,949...47,564,318

G

calcium/calmodulin-dependent protein kinase II alpha

treatment

RGD

NCBI chr18:56,648,779...56,711,505
Ensembl chr18:54,378,784...54,438,994

G

cytochrome P450, family 24, subfamily a, polypeptide 1

treatment

RGD

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 27, subfamily b, polypeptide 1

treatment

RGD

NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:62,871,297...62,876,241

G

glycine amidinotransferase

RGD

PMID:15462098 PMID:19664912

RGD:329961309, RGD:329961312

NCBI chr 3:130,112,508...130,137,664
Ensembl chr 3:109,658,951...109,684,129

G

GC, vitamin D binding protein

treatment

RGD

NCBI chr14:18,916,255...18,951,670
Ensembl chr14:18,632,135...18,667,567

G

glutathione peroxidase 3

treatment

RGD

PMID:23662110 PMID:27412471 PMID:22115772

RGD:401827919, RGD:401827925, RGD:401827924

NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,028,570...39,037,035

G

hepatitis A virus cellular receptor 1

treatment

RGD

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698

G

inositol 1,4,5-trisphosphate receptor, type 1

treatment

RGD

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:141,187,418...141,510,491

G

microRNA 494

RGD

NCBI chr 6:134,550,115...134,550,197
Ensembl chr 6:128,728,709...128,728,793

G

nitric oxide synthase 2

treatment

RGD

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

ryanodine receptor 1

treatment

RGD

NCBI chr 1:93,420,078...93,551,305
Ensembl chr 1:84,292,578...84,423,812

G

S100 calcium binding protein A1

treatment

RGD

NCBI chr 2:178,291,503...178,296,346
Ensembl chr 2:175,993,922...175,999,544

G

S100 calcium binding protein B

treatment

RGD

NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,881...12,394,743

G

transforming growth factor, beta 1

treatment

RGD

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

vitamin D receptor

treatment

RGD

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677

neurotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

myelin basic protein

treatment

RGD

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:75,855,878...75,966,404

G

myelin oligodendrocyte glycoprotein

treatment

RGD

NCBI chr20:1,514,110...1,528,716
Ensembl chr20:1,513,239...1,523,474

G

myelin regulatory factor

treatment

RGD

NCBI chr 1:216,279,057...216,311,155
Ensembl chr 1:206,854,175...206,886,157

G

proteolipid protein 1

treatment

RGD

NCBI chr X:104,933,921...104,993,317
Ensembl chr X:100,185,767...100,201,032

NSAID-Enteropathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 9

RGD

Ensembl chr 5:154,109,046...154,126,626

G

prostaglandin E receptor 3

treatment

RGD

NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin E receptor 4

treatment

RGD

NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:54,335,424...54,346,670

poor metabolism of thiopurines

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thiopurine S-methyltransferase

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Thiopurine S-methyltransferase deficiency
OMIM:610460

CTD
ClinVar
MouseDO

PMID:1960624 PMID:7862671 PMID:8561894 PMID:8644731 PMID:9177237 More...

NCBI chr17:17,850,308...17,868,976
Ensembl chr17:17,644,173...17,662,709

poor metabolism of thiopurines 1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thiopurine S-methyltransferase

ClinVar Annotator: match by term: THIOPURINES, POOR METABOLISM OF, 1 | ClinVar Annotator: match by term: TPMT-related condition

PMID:8561894 PMID:9931345 PMID:23400745 PMID:25741868

NCBI chr17:17,850,308...17,868,976
Ensembl chr17:17,644,173...17,662,709

poor metabolism of thiopurines 2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nudix hydrolase 15

ClinVar Annotator: match by term: NUDT15-related condition | ClinVar Annotator: match by term: Thiopurines, poor metabolism of, 2

PMID:22992668 PMID:25108385 PMID:25624441 PMID:26033531 PMID:26076924 More...

NCBI chr15:55,117,312...55,123,983
Ensembl chr15:48,709,700...48,747,363

Serotonin Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcium binding protein 1

protein:altered expression:postsynaptic density

RGD

NCBI chr12:47,045,914...47,109,614
Ensembl chr12:41,378,897...41,448,927

Serum Sickness

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

CTD Direct Evidence: marker/mechanism

PMID:350256 PMID:9380243

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836

Stevens-Johnson syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

CTD Direct Evidence: therapeutic

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836

G

amyloid P component, serum

CTD Direct Evidence: marker/mechanism

NCBI chr13:87,905,532...87,906,508
Ensembl chr13:85,373,220...85,374,298

G

complement C1q A chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q C chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:149,127,415...149,131,017

G

caveolin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:45,634,918...45,673,705

G

CUGBP, Elav-like family member 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:75,813,928...76,639,300
Ensembl chr17:71,210,853...71,728,333

G

complement factor H-related 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:53,946,298...53,961,282
Ensembl chr13:51,369,211...51,410,592

G

complement factor properdin

CTD Direct Evidence: marker/mechanism

NCBI chr X:3,715,551...3,721,113
Ensembl chr X:1,161,979...1,167,573

G

clusterin

mRNA:decreased expression:conjunctiva

RGD

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315

G

COP9 signalosome subunit 5

CTD Direct Evidence: marker/mechanism

NCBI chr 5:13,975,198...13,993,391
Ensembl chr 5:9,192,100...9,210,731

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 3

CTD Direct Evidence: therapeutic

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603

G

catenin beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111

G

cullin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:77,551,781...77,634,210
Ensembl chr 4:76,551,983...76,627,980

G

cullin 4A

CTD Direct Evidence: marker/mechanism

NCBI chr16:83,086,688...83,124,503
Ensembl chr16:76,384,546...76,422,330

G

derlin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:91,293,963...91,316,639
Ensembl chr 7:89,404,417...89,427,145

G

engulfment and cell motility 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:48,982,188...49,518,525
Ensembl chr17:44,286,485...44,822,788

G

E1A binding protein p300

CTD Direct Evidence: marker/mechanism

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

F-box protein 6

CTD Direct Evidence: marker/mechanism

NCBI chr 5:163,859,909...163,865,693
Ensembl chr 5:158,576,759...158,582,525

G

glutathione S-transferase mu 1

RGD

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411

G

interferon gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

lipopolysaccharide binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:146,954,015...146,981,586

G

leucine-rich alpha-2-glycoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:1,034,691...1,036,937
Ensembl chr 9:947,516...949,813

G

macrophage migration inhibitory factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:12,767,138...12,791,222
Ensembl chr20:12,790,902...12,799,504
Ensembl chr 4:12,790,902...12,799,504

G

microRNA 18a

CTD Direct Evidence: marker/mechanism

NCBI chr15:98,587,984...98,588,079
Ensembl chr15:92,180,765...92,180,860

G

NEDD4 E3 ubiquitin protein ligase

CTD Direct Evidence: marker/mechanism

NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:73,383,695...73,468,951

G

NFKB inhibitor zeta

NCBI chr11:58,251,720...58,279,767
Ensembl chr11:44,782,676...44,810,723

G

nitric oxide synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

nucleobindin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:105,104,793...105,135,730
Ensembl chr 1:95,968,326...96,003,220

G

orosomucoid 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:76,772,941...76,776,154

G

poly (ADP-ribose) polymerase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

PML nuclear body scaffold

CTD Direct Evidence: marker/mechanism

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:58,628,837...58,658,971

G

protein S

CTD Direct Evidence: marker/mechanism

NCBI chr11:13,676,310...13,757,858
Ensembl chr11:230,696...311,286

G

proteasome 26S subunit, ATPase 5

CTD Direct Evidence: marker/mechanism

NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,187,743...91,213,135

G

prostaglandin E receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin I2 synthase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:176,347,589...176,383,251
Ensembl chr 3:155,916,412...155,965,451

G

RB transcriptional corepressor 1

CTD Direct Evidence: marker/mechanism

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302

G

ring-box 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:114,870,893...114,881,194
Ensembl chr 7:112,990,835...113,001,051

G

RT1 class II, locus Bb

susceptibility

DNA:polymorphism:cds:HLA-DQB1*0601 (human)

RGD

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597

G

RT1 class I, locus CE13

susceptibility

DNA:polymorphisms:cds:HLA-B*5801 (human, Japanese)
DNA:polymorphisms:cds:HLA-B*15:02, HLA-B*40:01, HLA-B*58:02 (human)

RGD

PMID:19018717 PMID:23692434

RGD:7364874, RGD:7365090

NCBI chr20:3,314,491...3,322,815

G

RT1 class I, locus CE16

susceptibility

CTD Direct Evidence: marker/mechanism
ClinVar Annotator: match by term: Hypersensitivity syndrome, carbamazepine-induced, susceptibility to

CTD
OMIM
ClinVar

PMID:16538176 PMID:21428769 PMID:23588310

NCBI chr20:3,261,656...3,265,548
Ensembl chr20:3,257,123...3,279,563

G

tumor necrosis factor

protein:increased expression:blister:

RGD

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

valosin-containing protein

CTD Direct Evidence: marker/mechanism

NCBI chr 5:62,005,984...62,025,387
Ensembl chr 5:57,210,168...57,229,571

G

von Willebrand factor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:158,360,152...158,491,539

Tardive Dyskinesia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

treatment

associated with schizophrenia

RGD

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

dopamine receptor D3

associated with schizophrenia

RGD

NCBI chr11:70,385,586...70,437,793
Ensembl chr11:56,879,689...56,940,596

G

superoxide dismutase 2

associated with schizophrenia

RGD

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

Term paths to the root

Path 1
Term	Annotations
disease	19140
Chemically-Induced Disorders	1467
Drug-Related Side Effects and Adverse Reactions	667
Anticholinergic Syndrome	0
Cardiotoxicity +	33
Chemical and Drug Induced Liver Injury +	449
Chemotherapy-Related Cognitive Impairment	4
Chemotherapy-induced nausea and vomiting	0
Chloramphenicol Toxicity	0
Drug-Induced Akathisia	0
Drug-Induced Dyskinesia +	33
Drug-Induced Enteropathy +	4
Efavirenz, Poor Metabolism of	1
Metabolic Side Effects of Drugs and Substances	6
Myotoxicity	0
Propofol Infusion Syndrome	1
Serotonin Syndrome	1
chemotherapy-induced alopecia	0
drug allergy +	117
gastrointestinal toxicity	0
nephrotoxicity	18
neurotoxicity +	4
respiratory toxicity	0
vascular toxicity	0

paths to the root